EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment

Sibbeliene E van den Bosch iD, Willemijn E Corpeleijn, Barbara A Hutten iD, Albert Wiegman iD

Genes · 07.03.2023 · 14 (3) · 669

DOI: 10.3390/genes14030669 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 07.03.2023. Verfasst von Sibbeliene E van den Bosch und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Center…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Homozygous Familial Hypercholesterolemia, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Familial hypercholesterolemia (FH) is a hereditary disorder that causes severely elevated low-density lipoprotein (LDL-C) levels, which leads to an increased risk for premature cardiovascular disease. A variety of genetic variants can cause FH, namely variants in the genes for the LDL receptor (LDLR), apolipoprotein B (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and/or LDL-receptor adaptor protein 1 (LDLRAP1). Variants can exist in a heterozygous form (HeFH) or the more severe homozygous form (HoFH). If affected individuals are diagnosed early (through screening), they benefit tremendously from early initiation of lipid-lowering therapy, such as statins, and cardiovascular imaging to detect possible atherosclerosis. Over the last years, due to intensive research on the genetic basis of LDL-C metabolism, novel, promising therapies have been developed to reduce LDL-C levels and subsequently reduce cardiovascular risk. Results from studies on therapies focused on inhibiting PCSK9, a protein responsible for degradation of the LDLR, are impressive. As the effect of PCSK9 inhibitors (PCSK9-i) is dependent of residual LDLR activity, this medication is less potent in patients without functional LDLR (e.g., null/null variant). Novel therapies that are expected to become available in the near future focused on inhibition of another major regulatory protein in lipid metabolism (angiopoietin-like 3 (ANGPTL3)) might dramatically reduce the frequency of apheresis in children with HoFH, independently of their residual LDLR. At present, another independent risk factor for premature cardiovascular disease, elevated levels of lipoprotein(a) (Lp(a)), cannot be effectively treated with medication. Further understanding of the genetic basis of Lp(a) metabolism, however, offers a possibility for the development of novel therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHomozygous Familial HypercholesterolemiaHyperlipoproteinemia Type IIHumansChildProprotein Convertase 9Cholesterol, LDLCarrier ProteinsAngiopoietin-Like Protein 3

Stichwörter der Autor:innen

cholesterolfamilial hypercholesterolemiagenetic screeninglipid-lowering therapylipids

Substanzen

PCSK9 protein, humanProprotein Convertase 9Cholesterol, LDLCarrier ProteinsANGPTL3 protein, humanAngiopoietin-Like Protein 3

Autor:innen und Institutionen

  • Department of Pediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, The Netherlands.
  • Department of Epidemiology and Data Science, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, The Netherlands.

ORCID-Profile: Sibbeliene E van den Bosch, Barbara A Hutten, Albert Wiegman

Zitieren

APA

van den Bosch, S. E., Corpeleijn, W. E., Hutten, B. A., & Wiegman, A. (2023). How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment. Genes, 14(3), 669. https://doi.org/10.3390/genes14030669

Vancouver

van den Bosch SE, Corpeleijn WE, Hutten BA, Wiegman A. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment. Genes. 2023;14(3):669. doi:10.3390/genes14030669

BibTeX
@article{vandenBosch2023,
  author = {van den Bosch, Sibbeliene E and Corpeleijn, Willemijn E and Hutten, Barbara A and Wiegman, Albert},
  title = {How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment},
  journal = {Genes},
  year = {2023},
  volume = {14},
  number = {3},
  pages = {669},
  doi = {10.3390/genes14030669}
}
Kostenlos starten →